Personalized Cell Therapy Market 2024

The personalized cell therapy market size has grown exponentially in recent years. It will grow from $13.98 billion in 2023 to $17.11 billion in 2024 at a compound annual growth rate (CAGR) of 22.4%. The growth in the historic period can be attributed to increasing awareness of personalized medicine, increasing healthcare spending, increasing government initiatives, increasing funding for clinical research, rise in neurological disorders.

The personalized cell therapy market size is expected to see exponential growth in the next few years. It will grow to $38.52 billion in 2028 at a compound annual growth rate (CAGR) of 22.5%. The growth in the forecast period can be attributed to rising clinical trials, rising incidence of chronic illnesses, growing geriatric population, rising prevalence of cancer, and increasing adoption of regenerative medicines. Major trends in the forecast period include technological advancements, integration of AI, personalized vaccines, bioinformatics, and microfluidic technologies.

The rise in neurological disorders is expected to drive the growth of the personalized cell therapy market going forward. Neurological disorders are a group of conditions affecting the brain, spinal cord, and nerves, leading to symptoms such as impaired motor function, cognitive deficits, and sensory disturbances. Neurological disorders are occurring due to an aging population, environmental stressors, and lifestyle changes contributing to higher incidences of neurodegenerative diseases. Personalized cell therapy is required for neurological disorders as it offers tailored treatments that target specific patient needs, potentially restoring damaged neural tissue and improving outcomes in complex, individualized conditions. For instance, in December 2022, according to the Parkinson Foundation, a US-based government organization, the yearly incidence of Parkinson's disease (PD) among older persons is 50% greater than the existing estimate of 60,000 cases. Additionally, 1.2 million more Americans are predicted to have Parkinson's disease by 2030. Therefore, the rise in neurological disorders is driving the growth of the personalized cell therapy market.

Major companies operating in the personalized cell therapy market are focused on forming strategic partnerships to accelerate the development and commercialization of innovative therapies. These collaborations help companies pool resources, expertise, and technologies to enhance research and development capabilities, streamline clinical trials, and navigate regulatory pathways more efficiently. For instance, in October 2022, Century Therapeutics Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb (BMS), a US-based biopharmaceutical company, to develop and commercialize allogeneic cell therapies. This collaboration uses Century's innovative induced pluripotent stem cell (iPSC) technology to create engineered natural killer (NK) and T cell therapies to treat hematologic malignancies and solid tumors. The agreement encompasses the development of up to four distinct cell therapy programs, with the initial focus on two specific areas, acute myeloid leukemia (AML) and multiple myeloma. These programs will utilize engineered NK cells or gamma delta T cells derived from iPSCs.

In April 2022, Fujifilm Corp., a Japan-based manufacturer of biopharmaceuticals, acquired a cell therapy manufacturing facility from Atara Biotherapeutics Inc. for USD 100 million. The key aims of the acquisition are to expand Fujifilm's CDMO capabilities in advanced therapies, strengthen its manufacturing capacity and expertise, and support Atara's clinical pipeline. Atara is a US-based allogeneic T-cell immunotherapy company.

Major companies operating in the personalized cell therapy market are AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Cipla Limited, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd, Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc.

North America was the largest region in the personalized cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cell therapy marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the personalized cell therapy marker report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Personalized cell therapy refers to a type of medical treatment where a patient's own cells, or cells that are specifically tailored to them, are used to treat a disease or condition. This therapy is customized to the individual's unique biological profile, often involving the modification or manipulation of cells to enhance their therapeutic potential. The key advantage of personalized cell therapy is that it minimizes the risk of rejection and adverse reactions as the therapy is designed to be compatible with the patient's own body.

The main types of personalized cell therapy include lymphocytes, mesenchymal stem cells, hematopoietic stem cells, and others. Lymphocytes are a type of white blood cell that are part of the immune system and help the body fight disease. It uses various techniques such as platelet transfusions, bone marrow transplantation, packed red cell transfusions, and organ transplantation and is applied for cardiovascular diseases, neurological disorders, inflammatory diseases, diabetes, cancer, and others. It is used by various end-users, including hospitals, homecare, specialty clinics, and others.

The personalized cell therapy market research report is one of a series of new reports that provides personalized cell therapy market statistics, including personalized cell therapy industry global market size, regional shares, competitors with a personalized cell therapy market share, detailed personalized cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cell therapy industry. This personalized cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The personalized cell therapy market consists of revenues earned by entities by providing services such as c car-t cell therapy, stem cell transplantation, tissue regeneration, gene editing therapies and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized cell therapy market also includes sales of personalized cancer vaccines, cell therapy kits and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.